Abbott Laboratories
NYSE:ABTMedical - Devices
-$0.51 today
- Market cap
- $180.95B
- Beta
- 0.62
- P/E (TTM)
- 24.5
- EPS (TTM)
- $3.59
- Dividend yield
- 2.77%
Volume 7.02M
Average 13.17M
ABT Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Abbott LaboratoriesNYSE: ABT
Other Income / Expenses · Q3 FY2026 · quarter ended Sep 2026
Other income / expenses turns negative
Q3 FY2026 other income / expenses was -$245M, compared with $123M a year earlier. Trailing-twelve-month other income / expenses was -$789M.
Context
- Other income / expenses amounted to 0.9% of revenue in FY2025, up 0.5 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near -$245M or moves back toward the trailing-twelve-month quarterly average of -$197.25M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 418M USD
- Year-over-year change
- +122.3%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 418M | +122.3% |
| FY2024 | 2024-12-31 | 188M | -17.9% |
| FY2023 | 2023-12-31 | 229M | +508.9% |
| FY2022 | 2022-12-31 | (56M) | +94.3% |
| FY2021 | 2021-12-31 | (989M) | — |
Other Income / Expenses vs competitors
How ABT compares with its peers on the latest reported figures
- ABT's LTM Sep 2026 other income / expenses of -$789M is the 9th highest of the 10 companies compared; the peer median is -$528M.
- Its year-over-year change of -324.8% is the 7th highest of 10, against a peer median of +34.1%.
- Other income / expenses amounts to 1.6% of revenue for ABT, versus a peer median of 2.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | -$183M | +60.2% | — | 0.5% | |
| LTM Sep 2026 | -$400M | +66.4% | — | 1.6% | |
| LTM Sep 2026 | -$402M | +42.2% | — | 2.0% | |
| LTM Jun 2026 | -$412M | -398.3% | — | 6.3% | |
| LTM Jun 2026 | -$528M | -1527.0% | — | 2.6% | |
| LTM Jun 2026 | -$543M | +70.0% | — | 2.1% | |
| LTM Jun 2026 | -$645M | -3171.4% | — | 3.1% | |
| LTM Sep 2026 | -$646M | +34.1% | — | 1.4% | |
| LTM Sep 2026 | -$789M | -324.8% | — | 1.6% | |
| LTM Sep 2026 | -$7.79B | -204.5% | — | 7.8% | |
| Peer median (excluding ABT) | -$528M | +34.1% | — | 2.1% | |
Competitors are the stored peer set for ABT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 43.08B | 43.65B | 40.11B | 41.95B | 44.33B |
| Cost of Revenue | 19.86B | 21.33B | 20.07B | 20.63B | 19.72B |
| Gross Profit | 23.21B | 22.32B | 20.04B | 21.33B | 24.61B |
| Gross Margin | 53.9% | 51.1% | 50.0% | 50.8% | 55.5% |
| Research & Development | 2.74B | 2.85B | 2.72B | 2.82B | 2.96B |
| Selling, General & Admin | 11.28B | 11.11B | 10.88B | 11.65B | 12.38B |
| Operating Expenses | 14.01B | 13.96B | 13.6B | 14.47B | 16.59B |
| Depreciation & Amortization | 3.54B | 3.27B | 3.24B | 3.22B | 3.12B |
| EBITDA | 12.16B | 11.89B | 10.61B | 10.83B | 11.92B |
| EBITDA Margin | 28.2% | 27.2% | 26.4% | 25.8% | 26.9% |
| Operating Income | 9.2B | 8.36B | 6.44B | 6.83B | 8.05B |
| Operating Margin | 21.4% | 19.2% | 16.0% | 16.3% | 18.2% |
| Interest Income | 43M | 183M | 385M | 344M | 230M |
| Interest Expense | 410M | 315M | 698M | 603M | 341M |
| Other Income / Expenses | (989M) | (56M) | 229M | 188M | 418M |
| Income Before Tax | 8.21B | 8.31B | 6.66B | 7.01B | 8.47B |
| Pre-Tax Margin | 19.1% | 19.0% | 16.6% | 16.7% | 19.1% |
| Income Tax Expense | 1.14B | 1.37B | 941M | (6.39B) | 1.94B |
| Net Income | 7.07B | 6.93B | 5.72B | 13.4B | 6.52B |
| Net Margin | 16.4% | 15.9% | 14.3% | 31.9% | 14.7% |
| EPS (Basic) | 3.97 | 3.94 | 3.30 | 7.67 | 3.74 |
| EPS (Diluted) | 3.94 | 3.91 | 3.27 | 7.64 | 3.72 |
| Weighted Avg Shares | 1.78B | 1.75B | 1.73B | 1.73B | 1.75B |
| Weighted Avg Shares (Diluted) | 1.79B | 1.76B | 1.75B | 1.75B | 1.75B |
Abbott Laboratories
NYSE:ABT
Intrinsic Alpha fair value
Locked
Current Price
$104.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.